Lexeo's LX2006 Shows Early Efficacy in Friedreich Ataxia, Pivotal Trial Set for 2026
Event summary
- Lexeo Therapeutics published Phase I/II data for LX2006 in JAMA Cardiology, showing early signs of efficacy in Friedreich ataxia (FA).
- The SUNRISE-FA 2 pivotal study for LX2006 is set to initiate in Q2 2026, with topline data expected in 2H 2027.
- 17 participants were dosed across two studies, with 28% mean improvement in LVMI at 6 months and 33% at 12 months in mid- and high-dose cohorts.
- LX2006 was generally well-tolerated, with no Grade 3+ serious adverse events and minimal, transient liver function test elevations.
The big picture
Lexeo's publication in JAMA Cardiology underscores the potential of gene therapy in addressing the underlying cause of Friedreich ataxia cardiomyopathy, a progressive and life-threatening condition with no approved treatments. The initiation of the SUNRISE-FA 2 pivotal study marks a critical step in validating LX2006's efficacy and safety profile, positioning Lexeo as a key player in the genetic medicine space for cardiovascular diseases. The company's focus on leveraging pioneering science to treat genetic causes of cardiovascular conditions aligns with broader industry trends toward targeted, precision therapies.
What we're watching
- Clinical Validation
- How sustained improvements in LVMI and frataxin biomarker expression will translate into long-term efficacy in the pivotal trial.
- Regulatory Pathway
- Whether the FDA will accept the proposed registrational trial design for LX2006, given the early but promising data.
- Competitive Landscape
- The pace at which Lexeo can advance LX2006 through development, given the lack of approved cardiac-specific treatments for Friedreich ataxia.
Related topics